Treatment for hemophilia A consists of injecting the missing factor VIII I.V. to prevent or stop bleeding. A majority of the complications of this treatment are the development of antibodies against FVIII, called inhibitors.
The development of an anti-FVIII inhibitor leads to episodes of bleeding that are difficult to control.
The activity of the inhibitor is measured by a Bethesda test and is expressed in BU.
1BU neutralizes 50% of the activity of FVIII for hemophilia A.

Control titrated to the cut-off value according to HAS recommendations.

- The stability of the product is 7 days at -20 °C
- Bethesda Unit title depending on lots and tests (close to 1.5 Bethesda Unit)

- 25 cryotubes x 0.5 mL of frozen plasma